Clinical Trials Logo

Brain Stem Neoplasms clinical trials

View clinical trials related to Brain Stem Neoplasms.

Filter by:

NCT ID: NCT06243965 Completed - Clinical trials for Lymph Node Metastasis

Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?

DSR-MTC
Start date: January 1, 1997
Phase:
Study type: Observational

The oncologic benefit of lateral neck dissection (LND) during index operation for sporadic medullary thyroid carcinoma (MTC) basing on basal calcitonin (bCT) levels has been questioned due to the potential post-operative complications. This study aims to evaluate desmoplastic reaction (DSR), as predictor of nodal metastases, for definition of surgical strategy. Data from pathological report of MTC after operations between 1997 and 2022 were collected. The primary endpoint of the study was evaluating the risk factors for nodal metastases. The secondary endpoints analyzed the correlations between DSR and nodal metastases and the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of DSR for nodal metastases.

NCT ID: NCT06093165 Not yet recruiting - Clinical trials for Diffuse Intrinsic Pontine Glioma

RE-irradiation of Diffuse MIdline Glioma paTients

REMIT
Start date: October 2023
Phase: N/A
Study type: Interventional

The REMIT (RE-irradiation of diffuse MIdline glioma paTients) study evaluates safety and the palliative efficacy of re-irradiation of patients with diffuse midline glioma (DMG). The study will introduce a standard re-irradiation treatment schedule for DMG patients who have progressed following primary treatment.

NCT ID: NCT04668508 Recruiting - Glioma Clinical Trials

Anlotinib to Malignant Brainstem Glioma

Start date: November 24, 2020
Phase: Phase 2
Study type: Interventional

This study is a single-arm, open-label, phase II study of anlotinib combined with radiation in the treatment of patients with malignant brainstem glioma. Twenty five patients will be enrolled in the study who is diagonsis with malignant brainstem glioma. The primary objective includes disease control rate (DCR), the role of antinib combined with radiotherapy in improving quality of life and 6-month progression-free survival rate. The secondary objective include overall survival (OS), toxicity profile. Exploratory objectives include the use of plasma specimens and cerebrospinal fluid (if possible) to detect biomarkers predicting the efficacy of anlotinib.

NCT ID: NCT04280081 Active, not recruiting - Solid Tumor Clinical Trials

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

LIBRETTO-321
Start date: March 16, 2020
Phase: Phase 2
Study type: Interventional

The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

NCT ID: NCT04028479 Recruiting - Breast Cancer Clinical Trials

The Registry of Oncology Outcomes Associated With Testing and Treatment

ROOT
Start date: May 5, 2021
Phase:
Study type: Observational [Patient Registry]

This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. It will also create reusable infrastructure to allow creation or affiliation with many additional RWD/RWE efforts both prospective and retrospective in nature.

NCT ID: NCT03666507 Completed - Clinical trials for Vestibular Schwannoma

Vegetative Monitoring During Brainstem-associated Surgery

Start date: August 28, 2018
Phase:
Study type: Observational

Intraoperative Monitoring of Heart rate variability, Blood pressure variability, Baroreceptorsensivity etc.

NCT ID: NCT03352427 Terminated - Glioma Clinical Trials

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

Start date: December 6, 2017
Phase: Phase 2
Study type: Interventional

This trial will evaluate the activity of dasatinib in combination with everolimus for children with gliomas harboring PDGFR alterations, including newly diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) after radiation (stratum A); and recurrent/progressive glioma (grade II-IV, including DIPG) (stratum B).

NCT ID: NCT02780804 Completed - Clinical trials for Refractory Malignant Solid Neoplasm

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Start date: January 6, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.

NCT ID: NCT02672241 Recruiting - Clinical trials for Childhood Brain Stem Neoplasm

Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children

Start date: January 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of nimotuzumab in combination of radio-chemotherapy for the treatment of brainstem tumor in children.

NCT ID: NCT02644291 Completed - Glioblastoma Clinical Trials

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors

Start date: May 2016
Phase: Phase 1
Study type: Interventional

This is a safety (Phase 1) trial using mebendazole for recurrent pediatric brain cancers that include medulloblastoma and high grade glioma, that are no longing responding to standard therapies. The drug mebendazole is an oral drug in a chewable 500 mg orange flavored tablet. It is already approved to treat parasitic infections. The purpose of this study is to determine the safety and side effects for increasing doses of mebendazole, followed by the treatment of an additional 12 patients at the best tolerated dose.